– USA, CA – UNITY Biotechnology, Inc. (NASDAQ: UBX), a biotechnology company today announced the appointment of Michael Samar to its Board of Directors.
“We’re thrilled to add Michael to UNITY’s board of directors. With his strong background in biotech finance and operations, combined with an energetic fresh perspective and track record of execution, Michael’s strategic perspective will be vital as we focus on executing on our UBX1325 studies in DME and AMD and delivering key readouts this year,” said CEO, Dr. Anirvan Ghosh.
Michael Samar will also join the audit committee as its chair and the compensation committee as a member.
Concurrent with this appointment, Graham Cooper has stepped down from the board of directors.
About Michael Samar
Michael Samar currently serves as CFO of Assembly Bio, having been promoted from SVP of finance and business operations. His prior experience includes serving as VP of Finance and Site Head for the South San Francisco facility at Acorda Therapeutics; Director of Financial Planning and Analysis at Onyx Pharmaceuticals; Senior Finance Director, Global Planning and Analysis at Agennix and increasingly senior roles within finance at Johnson & Johnson Pharmaceutical R&D.
Mr. Samar obtained his MBA from Villanova University and his BS in finance from Bryant University.
He also serves as Treasurer on the Board of OUTbio Bay Area, Inc., a non-profit organization for LGBTQ+ professionals in the biotech and related industries.
About UNITY
UNITY is developing a new class of therapeutics to slow, halt, or reverse diseases of aging. UNITY’s current focus is on creating medicines to selectively eliminate or modulate senescent cells and thereby provide transformative benefit in age-related ophthalmologic and neurologic diseases.
For more information: https://unitybiotechnology.com
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.
